SPRAVATO® (Esketamine) is FDA-approved and a rapid-acting antidepressant for the treatment of depression.
Are you struggling with Treatment-Resistant Depression (TRD)?
If you’ve tried two or more oral antidepressants without relief, you’re not alone. But there’s hope. Introducing Spravato® Esketamine Therapy, the first and only FDA-approved nasal spray designed specifically for adults facing the challenges of TRD.
Is Spravato® Right for You?
If you’re still experiencing symptoms of depression despite trying multiple oral antidepressants, it may be time to discuss Spravato® with your healthcare provider. Adding Spravato® to your current treatment regimen could potentially offer the breakthrough you’ve been seeking. Adults with Major Depression Disorder (MDD), Suicidal Thoughts and TRD can opt for Spravato® Esketamine Therapy
What is Spravato®?
Spravato®, also known as Esketamine, is a nasal spray medication endorsed by the U.S. Food and Drug Administration (FDA) for treating Treatment-Resistant Depression (TRD) in adults. It functions as a fast-acting antidepressant, offering respite for individuals who have not responded adequately to at least two different antidepressant treatments.
Spravato® presents a fresh approach to depression treatment, particularly beneficial for those who have not experienced success with traditional oral antidepressants. Unlike conventional antidepressants, Spravato® operates uniquely by targeting NMDA receptors in the brain, introducing a novel mechanism of action that may yield relief when conventional treatments have fallen short.
How it is Used?
Following these steps ensures that the administration of Spravato nasal spray at Penfield Psychiatry Clinic is carefully managed for optimal effectiveness in treating the diagnosed illness.
01. Pre-Treatment Preparations
- Patients should abstain from eating for at least 2 hours and from drinking for 30 minutes prior to the treatment.
- Ensure that the Spravato nasal spray device is prepared for administration.
02. Administration of Spravato Nasal Spray
- Gently tilt your head back to a comfortable position.
- Insert the nasal spray device into one nostril and administer two sprays.
- Repeat the process for the other nostril, delivering two sprays.
- Ensure the patient remains in an upright position during and after administration.
03. Post-Treatment Monitoring
- Patients are monitored for a minimum of 2 hours post-treatment.
- Observations are made to manage and address any potential side effects that may arise.
04. Dosage Schedule
- Initially, treatment consists of twice-weekly sessions for the first four weeks.
- This is followed by once-weekly sessions for an additional four weeks.
- Dosage adjustments are made by the doctor based on improvements in the patient’s mental health.
What to Consider?
Before deciding on Spravato®, it’s important to thoroughly grasp its advantages and precautions. Not everyone may be suitable for Spravato®, particularly individuals with specific medical conditions or allergies. Consulting with your healthcare provider is essential to ascertain whether Spravato® is the appropriate option for you.
Individuals with conditions such as blood vessel disease (including aneurysmal vascular disease in various parts of the body) or arteriovenous malformation should avoid Spravato®. Additionally, if you have allergies to esketamine, ketamine, or any components of Spravato®, Esketamine Therapy should be avoided.
PARTNERS
We have covered with insurance companies
Get in-network and affordable care without the hassles. Our care team works directly with insurance companies to get coverage, file and process claims, and help with appeals when needed. We also offer affordable self-pay rates.
Get in touch with us
Rochester, New York, USA 481 Penbrooke Drive, Suite 6 Penfield, NY 14526
Begin your path towards mental wellness by connecting with us at Penfield Psychiatry. Reach out to us and allow our experienced team to assist you in exploring the potential of Spravato Esketamine Therapy. Your journey towards a brighter and healthier future starts now.